European Commission Authorizes IMCIVREE for 4+ Patients After 19.8% BMI Reduction
The European Commission has expanded marketing authorization of IMCIVREE for adults and children aged 4+ with acquired hypothalamic obesity, affecting roughly 10,000 patients in Europe. This approval follows Phase 3 TRANSCEND results showing a 19.8% placebo-adjusted BMI reduction at 52 weeks across 120 patients.
1. EC Approval Expands IMCIVREE Use
The European Commission has granted marketing authorization for setmelanotide, marketed as IMCIVREE, in adults and children aged 4 years and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. An estimated 10,000 patients in Europe may now access the first approved therapy for this condition, pending country-specific reimbursement decisions.
2. Phase 3 TRANSCEND Trial Results
Approval is based on data from the TRANSCEND trial involving 120 patients, which demonstrated a statistically significant 19.8% placebo-adjusted reduction in body mass index at 52 weeks. Adult participants (n=49) achieved a 19.2% adjusted decrease and pediatric patients (n=71) saw a 20.2% reduction, with common adverse events including nausea, vomiting, diarrhea and injection site reactions.
3. Launch Timeline and Access Strategy
Rhythm Pharmaceuticals plans commercial launches across European markets in 2027, following national pricing and reimbursement negotiations. The company will engage with local health authorities to support patient enrollment, reimbursement pathways and access programs for those living with acquired hypothalamic obesity.